Why Animal Health-Focused Zoetis Shares Are Trading Higher Today
Zoetis Inc (NYSE: ZTS) beats revenue expectations with 10% Y/Y increase. U.S. segment up 16%, international up 3%. FY24 guidance revised higher. ZTS shares up 4.66%.
BorgWarner Stock Jumps On Q1 Earnings: Revenues Beat, $500M Buyback, Strong Guidance, And More
BorgWarner's stock surges post-Q1 earnings beat, $500M buyback, raised FY24 guidance, and reiterated sales outlook.
Shell Q1: Earnings Power Shines Despite Revenue Headwinds
Shell's first-quarter FY24 results show a decline in net income but an increase in adjusted earnings and dividend. Share buyback program announced.
Consumer Goods Company Church & Dwight Predicts Weaker Bottom-Line For Q2 With Moderate Gross Margin Expansion
Church & Dwight exceeds expectations with a 5.1% year-on-year sales surge in Q1 FY24, reaching $1.50 billion, outpacing analyst projections.
Superior Industries International Sees FY24 Net Sales 1.38B-$1.48B Vs $1.38B Est.
2024 OutlookSuperior's full year 2024 Outlook is as follows: FY 2024 Outlook Net Sales$1.38 - $1.48 billion Value-Added
Alnylam Pharmaceuticals Reiterats 2024 Financial Guidance, Including Combined Net Product Revenues Of $1.4B-$1.5B
2024 Financial GuidanceFull year 2024 financial guidance is reiterated as follows:Combined net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO1 $1,400 million - $1,500 millionNet Product Revenue Growth
Omnicell Reaffirms FY24 Outlook: Adj EPS $0.90-1.40 vs $1.07 Est; Sees Sales $1.045B-1.120B vs $1.06B Est
The table below summarizes Omnicell's second quarter and full year 2024 guidance outlined above.
Q2 2024
2024
Bookings
Not
Frontier Group Expects Q2 Capacity To Grow By 12%-14%, For FY24 Capacity Will Grow Between 12%-15%
For second quarter, capacity is expected to grow by 12 to 14 percent over the comparable 2023 quarter. Pursuant to the shift to high-fare, underserved markets, a significant portion of scheduled capacity in
Belden Expects Q2 Adjusted EPS Of $1.30-$1.40 Vs. Consensus Of $1.34 And Revenue Of $565M-$580M Vs. Consensus Of $565.261M
Outlook
"Our solutions are being embraced by customers and partners, as our teams continue to lean into our transformation," said Dr. Chand. "The ever-increasing need for data and automation continues as